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signaling from these resistant tumor cells resulted in an 
additional level of treatment resistance towards the 
combined treatment modality of MSAs and ionizing radiation 
in vivo. However, combined treatment of MSAs with clinically 
relevant mTOR-signaling- or VEGF-antagonists strongly re-
sensitized MSA-resistant tumors (lung and colon carcinoma 
models) to the corresponding MSA. Interestingly, a novel 
clinically relevant microtubule-destabilizing agent, which is 
still active in MSA-resistant tumors, successfully overcame 
MSA-resistance in the lung and colon carcinoma models, 
downregulated the HIF1-alpha related aggressive tumor 
phenotype and strongly sensitized for ionizing radiation 
(bolus and metronomic scheduling). 
 
Conclusion: These data demonstrate that the interaction 
between the tumor cell compartment and the tumor 
microenvironment strongly determines the tumor response to 
the combined treatment modality of ionizing radiation and 
microtubule interfering agents. A combined treatment 
modality of microtubule interfering agents with 
antiangiogenic agents is potent to overcome tumor cell-
linked MSA-resistance and should be considered as clinical 
strategy for MSA-refractory tumor entities alone and in 
combination with radiotherapy. 
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Purpose or Objective: We aimed to evaluate the 
pathological hypoxic and perfusion effects of Trastuzumab 
(T) and/or Cisplatin (C) in HER2+ oesophageal 
adenocarcinoma xenograft (OE19) which may potentially 
direct future clinical adjunctive therapy. 
 
Material and Methods: SCID mice (n=17) bearing 
subcutaneous OE19 tumours were treated with either (i) 
Cisplatin 4mg/kg once a week, (ii) Trastuzumab 20mg/kg 
twice a week or (iii) Cisplatin and Trastuzumab for 2 weeks. 
Intraperitoneal Pimonidazole (Pm), an exogenous hypoxic 
marker, and intravenous Hoechst 33342 (Ho), a perfusion 
marker, were injected 2 hours and 1 minute prior to tumour 
excision, respectively. Tumours were immediately snap-
frozen and 10μm frozen sections were obtained for 
immunofluorescence study. Following fixation, non-specific 
binding was blocked using 10% normal goat serum. The 
sections were then incubated overnight at 4°C with primary 
Pimonidazole FITC labelled mouse monoclonal antibody at 
1:25 concentration. Propidium iodide (PI) was used as a 
counterstain to highlight morphology. Tumour sections were 
scanned using different filters for Pm (green), Ho (blue) and 
PI (red) on a fluorescence microscope at x100 magnification 
(Figure 1).  
 
 
 
Image analysis was performed using the ImageJ software. 
Percentage areas stained with Pm (hypoxic fraction/HF) and 
Ho (perfusion fraction/PF) were derived and mean (%) ± SD 
are presented. Difference in the HF and PF between 
Trastuzumab (T) and non-Trastuzumab (NT) treated animals 
were analysed. 
 
Results: Overall, tumour periphery was better perfused in 
most tumours but there was no consistent hypoxic 
intratumoral spatial localisation. There was an inverse spatial 
relationship between Pm and Ho fluorescence in 10/17 
tumours, colocalisation in 3/17 and no relationship found in 4 
tumours. Trastuzumab-treated tumours (HF 38%±17) were 
less hypoxic compared to the NT group (HF 50%±13) and these 
tumours were also better perfused (PF: T 46%±25, NT 
39%±16). Cisplatin-treated tumours had the highest HF 
(50%±13) and lowest PF (39%±16) compared to Trastuzumab 
(HF 34%±13, PF 48%±26) and combination therapy (HF 
41%±21, PF 45%±27). 
 
Conclusion: Trastuzumab appeared to exert the predominant 
proangiogenic effect with improved perfusion and reduced 
intratumoral hypoxia, although these effects were diminished 
with combination therapy. These data suggest that the 
addition of hypoxia-modifying agents might be tested as an 
adjunctive therapy, particularly in those not eligible or fit for 
Trastuzumab therapy. 
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